24+ products in Advanced Intermediates and API
11 products commercialization in FY 19
6 products are for scale up in FY 20
2 products are in pipeline for second source opportunity
1 product solo manufacturer in India and other alternative is Imports

Clientele Type

Pharmaceutical companies and Direct customers in API market


Through strategic partners and Direct marketing channel

Asking Price Includes

Product line and investment for factory and labs


Expansion and Working capital requirement

Other Details

Promoted by “Group Of Scientists” with Strong ‘Research & Development back ground in Generics Pharma Industry
 ~100 Years of combined generics experience
 ~100 Patents from past experience
 ~250 Molecules work experience in global pharmaceutical firms.
Key strength of building business is through research and development of “Complex Chemistry” molecules.
R&D Complete for 3 complex molecules.
2 Molecules Commercialized
Estimated Rev/Year: 1 st Molecule ₹20Cr – ₹29Cr, 2 nd Molecule ₹16Cr - ₹19Cr
3 rd Molecule to be Commercialized between July-Aug 2019
Estimated Rev/Year: ₹22Cr – ₹34Cr
More to come… Manufacturing Plant:
 ~10 acres plot at Vizag.
 cGMP plant with 42 Reactors (133 KL reactor capacity) in Phase – 1.
 Infrastructure ready for additional 14 reactors (60 KL Capacity), increasing total capacity to 56
reactors and 193 KL capacity. Total facility is expandable to ~100 reactors
The company started its R&D operations in 2015 in Hyderabad. Commercial sales of products started in December 2018, generating revenue of ₹22 Crores before Mar 31 st 2019. Company has a presence in India and through strategic partners has a presence in Europe, US, South Korea, Japan, and others. Manufacturing premise and process are as per USFDA and cGMP. Total R&D area is 6000 sqft and 33 fume hoods. Current manpower in the R&D department is 51 and in the production plant is 108. Company is looking to raise up to 3 Million USD for growth of their existing captive product line for both working Capital and Capex investments plans for their factory.

You may also like